Therefore, targeting autophagy may be a promising approach to improve the therapeutic efficacy of EGFR–TKIs in advanced NSCLC, which provides a new vision for reducing drug resistance of tumor-targeted therapy. Here, EGFR is linked to non-small cell lung carcinoma.